WO2023194601A8 - Inhibiteurs de l'activité mitochondriale dérivés de diamines pour leur utilisation dans le traitement du cancer - Google Patents

Inhibiteurs de l'activité mitochondriale dérivés de diamines pour leur utilisation dans le traitement du cancer Download PDF

Info

Publication number
WO2023194601A8
WO2023194601A8 PCT/EP2023/059306 EP2023059306W WO2023194601A8 WO 2023194601 A8 WO2023194601 A8 WO 2023194601A8 EP 2023059306 W EP2023059306 W EP 2023059306W WO 2023194601 A8 WO2023194601 A8 WO 2023194601A8
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
diamine
mitochondial
derivative
treatment
Prior art date
Application number
PCT/EP2023/059306
Other languages
English (en)
Other versions
WO2023194601A1 (fr
Inventor
Marc BILLAUD
Martine CORDIER-BUSSAT
Peggy Suzanne
Patrick Dallemagne
Samir YAHIAOUI
Original Assignee
Centre National De La Recherche Scientifique
Universite Claude Bernard Lyon 1
Institut National De La Sante Et De La Recherche Medicale
Centre Leon Berard
Universite De Caen Normandie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique, Universite Claude Bernard Lyon 1, Institut National De La Sante Et De La Recherche Medicale, Centre Leon Berard, Universite De Caen Normandie filed Critical Centre National De La Recherche Scientifique
Publication of WO2023194601A1 publication Critical patent/WO2023194601A1/fr
Publication of WO2023194601A8 publication Critical patent/WO2023194601A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention s'applique au domaine thérapeutique du cancer. En particulier, l'invention est relative à un composé dérivé d'une diamine aliphatique comprenant au moins un motif pyridine ou pyrimidine, pour son utilisation comme agent anticancéreux, à une composition thérapeutique comprenant ledit composé, à un produit comprenant un tel composé et un autre actif, ainsi qu'à un tel composé.
PCT/EP2023/059306 2022-04-08 2023-04-07 Inhibiteurs de xophos pour leur utilisation dans le traitement du lymphome b WO2023194601A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRFR2203261 2022-04-08
FR2203261A FR3134311A1 (fr) 2022-04-08 2022-04-08 Nouveaux composés anticancéreux

Publications (2)

Publication Number Publication Date
WO2023194601A1 WO2023194601A1 (fr) 2023-10-12
WO2023194601A8 true WO2023194601A8 (fr) 2024-03-07

Family

ID=82100798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/059306 WO2023194601A1 (fr) 2022-04-08 2023-04-07 Inhibiteurs de xophos pour leur utilisation dans le traitement du lymphome b

Country Status (2)

Country Link
FR (1) FR3134311A1 (fr)
WO (1) WO2023194601A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2429530B1 (fr) * 2009-05-14 2018-11-07 The General Hospital Corporation (s)-méclozine destinée au traitement d'une blessure de l'ischémie-réperfusion
EP3886828A1 (fr) 2018-11-28 2021-10-06 Centre Léon Bérard Inhibiteurs d'activité mitochondriale ciblant le métabolisme de cellule tumorale

Also Published As

Publication number Publication date
WO2023194601A1 (fr) 2023-10-12
FR3134311A1 (fr) 2023-10-13

Similar Documents

Publication Publication Date Title
MX2021011826A (es) Composiciones y combinaciones farmacéuticas que comprenden inhibidores del receptor de andrógenos y usos de estas.
MX2023007192A (es) Inhibidores de prmt5.
CR20230404A (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
MX2021001884A (es) Compuestos de pirazina y usos de los mismos.
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
MX2023006145A (es) Inhibidores de prmt5 novedosos.
WO2009129531A3 (fr) Formulation de bupivacaïne dans un support polyorthoester
MX2022001004A (es) Inhibidores de enzimas.
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
WO2014179154A3 (fr) Nouveaux composés qui sont des inhibiteurs d'erk
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
MXPA05012675A (es) Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2021008667A (es) Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo.
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MX2023009520A (es) Compuesto de 4-aminoquinazolina.
EP4234021A3 (fr) Composition pharmaceutique contenant un dérivé d'adénosine destinée a la prévention ou au traitement de la néphropathie diabétique
WO2022221528A3 (fr) Inhibiteurs de kras g12c
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
WO2023194601A8 (fr) Inhibiteurs de l'activité mitochondriale dérivés de diamines pour leur utilisation dans le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23717921

Country of ref document: EP

Kind code of ref document: A1